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C
hronobiology is the term applied to
the study of how body rhythms are
governed by our environment,
starting with the solar system, which
cycles night and day and changes one
season into another (1). Bodily responses
encompassed by chronobiology determine
both everyday behavior and expression
of illness (2). Key rhythms modulating
health and diseasestates may becircadian
(lasting about 24 h and deﬁning sleep-
awake patterns) or infradian (lasting longer
than 24 h, as in monthly menstruation).
Adjusting timing of medical treatment to
its differing effects depending on the pa-
tient’s circadian state as currently applied
in nocturnal asthma (3) and arthritis (4)
iscalledchronotherapy.Hermidaetal.(5)re-
port a prospective, randomized, open-label,
blinded end point trial of how varying the
time of day during which antihyperten-
sivedrugsaretakenmayaffectcardiovas-
cular risk in hypertensive patients with
type 2 diabetes.
That chronotherapy might assist in
management of hypertension was appre-
ciated by Bartter et al. (6) in a retrospective
24-h study of a single patient with systolic
and diastolic hypertension treated with
hydrochlorthiazide in 1976. Availability
of continuous 24-h blood pressure moni-
toringdevicespromptedaFrenchstudyin
1985 suggesting that each hypertensive
patient be evaluated over a full day with
subsequent antihypertensive drug treat-
ment scheduled to ﬁt daily periods of
highest pressure (7). Noting that “many
cardiovascular disorders occur with great-
est frequency between 06:00 and 12:00
AM,” Cooke and Lynch (8), in 1994, pro-
posed that a chronotherapeutic approach
to therapy might proffer advantage in
thromboembolism, hypertension, angina,
and acute myocardial infarction by facili-
tating improved patient outcomes. Pre-
dicting that chronotherapy for ischemic
heart disease would be forthcoming, the
University of Texas established a chrono-
biology department in 1996 (9). As newer
classes of antihypertensive drugs have
been introduced, focused attention on
blood pressure during sleep increased
with growing hope that cardiovascular
complications might be reduced in fre-
quency and intensity (10).
The study by Hermida et al. of 448
hypertensivepatientswithtype2diabetes
who had ambulatory blood pressure
measured initially for 48 h and then
annually over a mean of 5.4 years found
that administering antihypertensive med-
ications at bedtime produced a signiﬁ-
cantly lower cardiovascular risk (adjusted
by sex and age) than that in a randomly
selected cohort given their antihyperten-
sive drugs upon awakening. Taking anti-
hypertensivedrugsat bedtimesigniﬁcantly
decreased the adjusted risk of cardiovascu-
lardeath,myocardialinfarction,andstroke
(0.25; P 5 0.003). Bedtime treatment
signiﬁcantly reduced both sleep-time
blood pressure mean with a 12% cardio-
vascular risk reduction per 5 mmHg de-
crease in asleep systolic pressure during
follow-up.
It is well known that shift workers
have increased diabetes and obesity,
worse glucose control, and higher rates
of cardiovascular disease and mortality
(11). Changing the clocks back in spring
is associated with increased myocardial
infarctions. Supporting these observa-
tions are short-term experimental studies
showing that misalignment of behavioral
andcircadiancyclesresultsinadversecar-
diometabolic end points including higher
arterial blood pressure, glucose, insulin,
ghrelin, cortisol, and catecholamines
(12). Genetic studies point to molecular
mechanisms based in highly conserved
controllers of periodicity or Zeitgaber
(13,14). These molecular clocks are
located in the central nervous system
and in peripheral tissue, communicating
with each other and responding to a great
number of inputs presumably designed
to maintain homeostasis of the entire or-
ganism relative to changing environ-
ments.
AnarticlebyHermidaetal.(15)dem-
onstrating that treatmentsynchronizedto
the biology of hypertension is highly ef-
fective in diabetes and nondiabetes gives
support to the concept that treatment
synchronized to the biology of metabo-
lism might also be effective especially as
glycemia is particularly difﬁcult to man-
agement. There is some use of chronother-
apy in current glycemia treatment; how-
ever, it is not a major focus. For example,
bedtime insulin is used to lower the ten-
dency of the blood glucose to rise in the
morning. The conventional explanation is
that insulin counters the tendency to in-
crease hepatic glucose production by the
normal nocturnal surge in growth hor-
mone and cortisol. However, newer data
suggest a greater complexity—liver cells
themselveshavemolecularclocksthatgov-
ern hepatic glucose production and fat
storage suggesting regulation of hepatic
steatosis (16). Meal-associated insulin
treatmenttargetstheexpectedpostprandial
rise in blood glucose. Indeed, molecular
genetic studies identify a clock gene for
b-cell mitochondrial function that in part
governsinsulinsecretion.Thenewtechnol-
ogyof24-hcontinuousglucosemonitoring
promisesinsightsintohow we mightbetter
deﬁne normalcy and tailor glycemic treat-
ment. Another example is the use of statin
therapyatbedtimetolowerLDLcholesterol
because lipid metabolism is nocturnal. The
study by Hermida et al. (5) prompts us to
reexamine the basisfor management ofgly-
cemia through the lens of chronobiology.
A key strength of the report by
Hermida et al. (5) is that it conﬁrms the
well known J curve for adverse outcomes
in systolic blood pressure as measured
in a clinic but shows no such effect for
systolic blood pressure while asleep, for
which the lowest blood pressure is asso-
ciated with the lowest hazard ratio. The
recentlypublishedActiontoControlCar-
diovascular Risk in Diabetes (ACCORD)
trial failed to show a difference in major
cardiovascular outcomes between inten-
siveand nonintensivesystolicbloodpres-
sure targets of ,120 and ,140 mmHg,
respectively (17). Had the investigators
considered the pragmatic reality of drug
effect possibly being altered by chrono-
biology, their results might have differed,
a st h et i m i n go fd o s i n go fb l o o dp r e s s u r e
medications was not standardized. Other
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EDITORIAL (SEE HERMIDA ET AL., P. 1270)possible variables that may have altered
the effect of antihypertensive treatment
during the study include differences in
lifestyle and behavior practices including
meditations, exercise, diet, stress reduc-
tion, and sleep hygiene policies.
At the least, Hermida et al. proffer a
strong argument for establishing each
newly managed hypertensive diabetic
patient’s circadian pattern of time-related
blood pressure elevation as a potential
correctable variable when designing an
individualized antihypertensive regimen.
In a larger perspective, we should be alert
to ignoring inherent cycles of nature that
contribute to establishing blood pressure
responses as well as, according to some
investigators, the basis of our growing
obesity pandemic. Awareness and re-
sponse to ticking biological clocks must
be kept in mind when constructing perti-
nent therapies, as evidence now supports
the thesis that knowledge of chronobiol-
ogy is a concern when building a chrono-
therapy for hypertension (18).
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